Trials / Unknown
UnknownNCT05235906
A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer
An Open-label, Single Center, Phase II Study of Surufatinib Combined With Sintilimab in Patients With Advanced Adenocarcinoma of the Gastric or Gastrooesophageal Junction Adneocarcinoma Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The efficacy and safety of the use of Surufatinib in combination with Sintilimab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Surufatinib+Sintilimab | Surufatinib at a dose of 250mg Qd, with humanized anti-PD-1 monoclonal antibody Sintilimab injected intravenously 200mg per 3 weeks until disease progresses or unacceptable tolerability occurs. |
Timeline
- Start date
- 2022-08-16
- Primary completion
- 2024-03-31
- Completion
- 2025-03-31
- First posted
- 2022-02-11
- Last updated
- 2023-08-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05235906. Inclusion in this directory is not an endorsement.